×
About 5,168 results

ALLMedicine™ Aplastic Anemia Center

Research & Reviews  1,426 results

Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese pa...
https://doi.org/10.1007/s12185-022-03496-5
International Journal of Hematology; Kanda Y, Mori T et. al.

Nov 29th, 2022 - Aplastic anemia results from lymphocyte-mediated destruction of hematopoietic stem cells. Immunosuppressive therapy with anti-thymocyte globulin (ATG) and cyclosporine is the standard front-line treatment for patients with severe aplastic anemia w...

Interleukin-10 promoter variability is associated with the susceptibility, severity, an...
https://doi.org/10.1111/ijlh.13993
International Journal of Laboratory Hematology; Wang S, You Y et. al.

Nov 19th, 2022 - Acquired aplastic anemia (AA), a heterogeneous bone marrow (BM) failure disease, is mainly mediated by the immune destruction of hematopoietic stem cells (HSCs). Given the predominant role of immunosuppressive therapy (IST) in AA, it is sensible t...

Molecular mechanisms underlying the role of HLA-DQ in systemic immune activation in sev...
https://doi.org/10.1016/j.bcmd.2022.102708
Blood Cells, Molecules & Diseases; Shao Y, Liu B et. al.

Nov 6th, 2022 - Severe aplastic anemia (SAA) is a bone marrow failure disorder caused by autoimmune dysfunction. The presentation by dendritic cells (DCs) is the key step in initiating the immune response against unknown antigens in SAA patients. In the previous ...

Aplastic anemia: a new complication in the recent mysterious hepatitis outbreak among c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632563
Journal of Medical Case Reports; Ghanei-Shahmirzadi A, Reihani H et. al.

Nov 5th, 2022 - Recently, an unknown hepatitis outbreak among children has concerned many individuals worldwide. These cases are frequently reported, mainly from Europe and other countries. In this study, we present two similar patients, who, to the best of our k...

Feasibility of electronic patient-reported outcome monitoring and self-management progr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631592
Annals of Hematology; Bänziger S, Weisshaar K et. al.

Nov 4th, 2022 - Electronic patient-reported outcomes (ePRO) are increasingly recognized in health care, as they have been demonstrated to improve patient outcomes in cancer, but have been less studied in rare hematological diseases. The aim of this study was to d...

see more →

Guidelines  1 results

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellula...
https://doi.org/10.3324/haematol.13755
Haematologica Bennett JM, Orazi A

Jan 16th, 2009 - Members of the French-American-British Cooperative Leukemia Working Group met to review cases of aplastic anemia, hypocellular myelodysplastic syndrome and hypocellular acute myeloid leukemia. Criteria were proposed and modified following three wo...

see more →

Drugs  229 results see all →

Clinicaltrials.gov  229 results

Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
https://clinicaltrials.gov/ct2/show/NCT03988608

Oct 14th, 2022 - This is a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag will be started at 25 mg/day and increas...

Improving White Blood Cell Collection From Healthy Donors
https://clinicaltrials.gov/ct2/show/NCT01553214

Oct 14th, 2022 - Bacterial and fungal infections in neutropenic patients or in patients with inherited disorders of neutrophil function continue to cause substantial morbidity and mortality. In particular, fungal infections are an increasingly important cause of d...

Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
https://clinicaltrials.gov/ct2/show/NCT02979873

Oct 13th, 2022 - Most acquired aplastic anemia ensues from immune-mediated destruction of hematopoietic stem and progenitor cells. Immunosuppression is the definitive treatment of patients with acquired aplastic anemia who are not candidates for immediate hematopo...

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
https://clinicaltrials.gov/ct2/show/NCT00003838

Oct 7th, 2022 - Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and...

Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
https://clinicaltrials.gov/ct2/show/NCT05571332

Oct 7th, 2022 - This is a multicenter, single-arm clinical study to evaluate the efficacy and safety of Avatrombopag combined with IST as the first-line regimen for aplastic anemia. The patients are diagnosed as hepatitis associated with very sever/sever aplastic...

see more →

News  165 results

Azacitidine-Based Combinations Represent New Treatment Possibilities in MDS
https://www.onclive.com/view/azacitidine-based-combinations-represent-new-treatment-possibilities-in-mds

Nov 2nd, 2022 - The exploration of combination therapies with an azacitidine (Vidaza) backbone could alter the treatment landscape for patients with myelodysplastic syndromes (MDS), according Mikkael A. Sekeres, MD, MS. Data are expected soon from the phase 3...

First-Line Treatment for Metastatic TNBC: Pembrolizumab + Chemotherapy
https://www.onclive.com/view/first-line-treatment-for-metastatic-tnbc-pembrolizumab-chemotherapy

Oct 11th, 2022 - Transcript: Segment Description:Comprehensive insight on use of first-line pembrolizumab plus chemotherapy in patients diagnosed with metastatic TNBC based on results from the KEYNOTE-355 trial. Aditya Bardia, MD, MPH: For a patient with PD-L1...

Olaparib Plus Bevacizumab Maintenance Therapy Provides OS Benefit in Advanced HRD-Positive Ovarian Cancer
https://www.onclive.com/view/olaparib-plus-bevacizumab-maintenance-therapy-provides-os-benefit-in-advanced-hrd-positive-ovarian-cancer

Sep 9th, 2022 - Maintenance olaparib (Lynparza) plus bevacizumab (Avastin) following first-line standard-of-care treatment improved overall survival (OS) in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination de...

Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD
https://www.onclive.com/view/topical-ruxolitinib-shown-to-be-effective-and-tolerable-in-cutaneous-cgvhd

Apr 25th, 2022 - Topical ruxolitinib (Opzelura) has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease (cGVHD) vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Trans...

Novel Gene Signature Found in Cutaneous Chronic GVHD Responders to Topical Ruxolitinib
https://www.onclive.com/view/novel-gene-signature-found-in-cutaneous-chronic-gvhd-responders-to-topical-ruxolitinib

Apr 24th, 2022 - A differentially expressed gene profile was identified in patients with cutaneous nonsclerotic and superficially sclerotic chronic graft-vs-host-disease (GVHD) who responded to treatment with topical ruxolitinib (Jakafi), according to findings fro...

see more →

Patient Education  17 results see all →